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irolimus-Eluting Versus Paclitaxel-Eluting
tent Implantation for the Percutaneous
reatment of Left Main Coronary Artery Disease
Combined RESEARCH and T-SEARCH Long-Term Analysis
arco Valgimigli, MD, Patrizia Malagutti, MD, Jiro Aoki, MD, Héctor M. Garcia-Garcia, MD,
aston A. Rodriguez Granillo, MD, Carlos A. G. van Mieghem, MD, Jurgen M. Ligthart, BSC,
ndrew T. L. Ong, MBBS, FRACP, George Sianos, MD, PHD, Evelyn Regar, MD, PHD,
on T. Van Domburg, PHD, Pim De Feyter, MD, PHD, Peter de Jaegere, MD, PHD,
atrick W. Serruys, MD, PHD
otterdam, the Netherlands
OBJECTIVES The purpose of this study was to investigate the long-term clinical and angiographic profile
of sirolimus-eluting stent (SES) versus paclitaxel-eluting stent (PES) in patients undergoing
percutaneous intervention for left main (LM) coronary disease.
BACKGROUND The long-term clinical and angiographic impact of SES as opposed to PES implantation in
this subset of patients is unknown.
METHODS From April 2002 to March 2004, 110 patients underwent percutaneous intervention for LM
stenosis at our institution; 55 patients were treated with SES and 55 with PES. The two
groups were well balanced for all baseline characteristics.
RESULTS At a median follow-up of 660 days (range 428 to 885), the cumulative incidence of major
adverse cardiovascular events was similar (25% in the SES group vs. 29%, in the PES group;
hazard ratio 0.88 [95% confidence interval 0.43 to 1.82]; p  0.74), reflecting similarities in
both the composite death/myocardial infarction (16% in the SES group and 18% in the PES
group) and target vessel revascularization (9% in the SES group and 11% in the PES group).
Angiographic in-stent late loss (mm), evaluated in 73% of the SES group and in 77% of the
PES group, was 0.32  74 in the main and 0.36  0.59 in the side branch in the SES group
vs. 0.46  0.57 (p  0.36) and 0.52  0.42 (p  0.41) in the PES group, respectively.
CONCLUSIONS In consecutive patients undergoing percutaneous LM intervention, PES may perform closely
to SES both in terms of angiographic and long-term clinical outcome. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.0402006;47:507–14) © 2006 by the American College of Cardiology Foundation
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Soutine drug-eluting stent (DES) implantation, by reducing
he need for target vessel revascularization (TVR) and angio-
raphic restenosis, has been recently proposed as the preferred
trategy in poor surgical candidates undergoing percutane-
us left main coronary artery (LM) intervention (1–3).
The longest average follow-up available for this treatment
s currently one year, and whether sirolimus-eluting stent
SES) or paclitaxel-eluting stent (PES) is performing better
n these patients is unknown (1–3).
Similarly, even for more conventional lesions, the differ-
ntial safety and efficacy profile of these two DES options is
argely debated (4–8). When taken together, current evi-
ence possibly suggests that in more complex lesion/patient
ubsets, SES performs better and more safely than PES
4–7,9).
From the Erasmus Medical Center, Thoraxcenter, Rotterdam, the Netherlands.
his study was supported by the Erasmus Medical Center, Rotterdam, and by
nrestricted institutional grants from Boston Scientific Corporation (Natick, Massa-
husetts) and Cordis, a Johnson & Johnson company (Warren, New Jersey).a
Manuscript received June 7, 2005; revised manuscript received August 24, 2005,
ccepted September 8, 2005.The percutaneous management of LM lesions is a chal-
enging intervention, where bifurcated vessels, extensive
all calcification, and poor hemodynamic tolerance often
oexist during treatment.
The purpose of the present study was to investigate, in a
igh-risk subset of patients undergoing revascularization in
tertiary referral center, the differential long-term impact of
ES compared with PES in terms of clinical and angio-
raphic outcome. Intravascular ultrasound analysis has also
een carried out at follow-up to quantity neointimal hyper-
lasia volume.
ETHODS
tudy design and patient population. Since April 16,
002, SES (Cypher; Johnson & Johnson-Cordis, Warren,
ew Jersey) has been used as a default strategy for every PCI
t our institution as part of the Rapamycin-Eluting Stent
valuated at Rotterdam Cardiology Hospital (RESEARCH)
egistry. From the first quarter of 2003, PES (Taxus; Boston
cientific Corp., Natick, Massachusetts) became commercially
vailable, replacing SES as the strategy of choice in every PCI,
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Drug-Eluting Stent for LM Treatment February 7, 2006:507–14s part of the Taxus-Stent Evaluated at Rotterdam Cardiology
ospital (T-SEARCH) registry. As a policy, all elective
atients presenting with significant (50% by visual estima-
ion) LM disease, referred to our institution for coronary
evascularization, are evaluated both by interventional cardiol-
gists and by cardiac surgeons, and the decision to opt for PCI
r surgery is reached by consensus as previously described (1).
From April 16, 2002, to March 6, 2004, a total of 110
onsecutive patients were treated exclusively with one or
ore DES in the LM as part of an elective or nonelective
evascularization procedure and constitute the patient pop-
lation of the present report. Fifty-five patients first received
xclusively SES, available at that time in diameters from
.25 to 3.00 mm, and then 55 patients received PES,
vailable in diameters from 2.25 to 3.5 mm. To ensure
omparability between the two study groups, the Parsonnet
urgical risk score, based on both clinical presentation profile
nd comorbidities, and the William Beaumont Hospital
implified scoring system were calculated for each patient
10,11). Nonelective treatment was defined as a procedure
arried out on referral before the beginning of the next
orking day (12).
The protocol was approved by the hospital ethics com-
ittee and is in accordance with the Declaration of Hel-
inki. Written informed consent was obtained from every
atient.
rocedures and postintervention medications. All inter-
entions were performed according to current standard
uidelines, and, except for the stent utilization, the final
nterventional strategy was left entirely to the discretion of
he operator. Angiographic success was defined as residual
tenosis 30% by visual analysis in the presence of Throm-
olysis In Myocardial Infarction (TIMI) flow grade 3. All
atients were advised to maintain aspirin lifelong, and
lopidogrel was prescribed for 6 months in both groups.
nd point definitions and clinical follow-up. The occur-
ence of major adverse cardiac events, defined as death,
onfatal myocardial infarction, or target vessel revascular-
Abbreviations and Acronyms
BMS  bare-metal stent
BR  binary restenosis
CX  left circumflex coronary artery
DES  drug-eluting stent
IVUS  intravascular ultrasound
LAD  left anterior descending coronary artery
LL  late loss
LM  left main coronary artery
MACE  major adverse cardiac events
MI  myocardial infarction
MLD  minimal luminal diameter
PES  paclitaxel-eluting stent
RCA  right coronary artery
SES  sirolimus-eluting stent
TVR  target vessel revascularizationzation, was recorded. Patients with more than one event
p
sere assigned the highest ranked event, according to the
revious list. End point definitions were previously reported
1). In order to make the clinical follow-up of the two
equential cohorts of patients comparable, clinical outcome
f the SES cohort was censored at two years.
uantitative angiographic and intravenous ultrasound
nalysis. Quantitative analyses of all angiographic data
ere performed with the use of edge-detection techniques
CAAS II; Pie Medical, Maastricht, the Netherlands). A
alue of 0 mm was assigned for the minimal luminal
iameter (MLD) in cases of total occlusion at baseline or
ollow-up. Binary restenosis (BR) was defined as stenosis of
50% of the luminal diameter in the target lesion. Acute
ain was defined as the MLD after the index procedure
inus the MLD at baseline angiography. Late loss (LL)
as defined as the MLD immediately after the index
rocedure minus the MLD at angiographic follow-up.
uantitative angiographic measurements of the target le-
ion were obtained in the in-lesion zone (including the
tented segment as well as the margins 5 mm proximal and
istal to the stent). Intravascular ultrasound (IVUS) analysis
as performed after administration of 200 g of intracoro-
ary nitroglycerin, with an automated pullback at 0.5 mm/s.
ll IVUS procedures were recorded on VHS videotape, and
able 1. Baseline Characteristics of the Study Population
Variables
SES Group
(n  55)
PES Group
(n  55)
p
Value
ge (yrs)* 64  12 63  12 0.54
ales (%)* 64 58 0.84
ody mass index (kg/m2)* 23  4 25  5 0.31
iabetes (%)* 34 24 0.29
ypertension (%)* 54 53 0.99
ypercholesterolemia (%) 58 56 0.99
urrent smokers (%) 16 20 0.8
reatinine (mol/l)* 96  32 100  80 0.68
V ejection fraction (%)* 44  16 44  12 0.95
edical history (%)
Protected left main 18 15 0.80
PCI 31 33 0.99
Myocardial infarction 38 47 0.44
TIA/stroke 9 11 0.74
Heart failure* 16 16 0.99
COPD severe*† 4 5 0.99
Peripheral arterial disease* 22 16 0.63
Carotid artery disease* 9 5 0.71
linical presentation (%)
Stable angina 49 45 0.86
Silent ischemia 0 4 0.12
Unstable angina 33 33 0.99
Acute myocardial infarction* 15 18 0.72
Cardiogenic shock at entry* 9 9 0.99
arsonnet score 20  13 17  11 0.27
illiam Beaumont Hospital
score‡
7.7  4.28 7.36  4.7 0.73
Parameter included in the Parsonnet classification. †Resulting in functional disabil-
ty, hospitalization, requiring chronic bronchodilatator therapy, or FEV1 75% of
redicted. ‡Based on age 65 years, creatinine elevation, multivessel disease, and
ccurrence of myocardial infarction within the previous 14 days.
COPD  chronic obstructive pulmonary disease; LV  left ventricular; PCI 
ercutaneous coronary intervention; PES  paclitaxel-eluting stent; SES 
irolimus-eluting stent; TIA  transient ischemic attack.
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February 7, 2006:507–14 Drug-Eluting Stent for LM Treatmentmages were digitized for analysis. A computer-based con-
our detection was performed with Qurad QCU analysis
oftware (Curad, Wijk Bij Duurstede, the Netherlands) as
reviously described (13). Intimal hyperplasia volume was
alculated as stent volume minus luminal volume. Percent-
ge intimal hyperplasia was defined as intimal hyperplasia
olume divided by stent volume.
tatistical analysis. The sample size was calculated on the
ssumption that average late loss in the SES and PES group
ould be around 0.15 mm and 0.35 mm, respectively, based
n previous findings. To detect this effect size with a sigma
alue of 0.3, 85% power, and a type I error (alpha) of 0.05,
2 patients per group were required. Continuous variables
re shown as mean  standard deviation (SD) and were
ompared using Student unpaired t test. Categorical vari-
bles are presented as counts and percentages and compared
ith the Fisher exact test. Survival curves were generated by
he Kaplan-Meier method, and survival among groups was
ompared using the log rank test. Cox proportional hazards
odels were used to assess risk reduction of adverse events.
ultivariable analysis, considering all variables reported in
ables 1 and 2 with a p value of less than 0.10, was
erformed to adjust for possible confounders and identify
hether the stent received was an independent predictor of
dverse events. Probability was significant at a level of
Table 2. Angiographic and Procedural Charact
Variables
Lesion location (%)*
Ostium
Body
Distal
Pure left main disease (%)
LM plus 1-vessel disease (%)
LM plus 2-vessel disease (%)
LM plus 3-vessel disease (%)
Right coronary artery 70% stenosis (%)
Right coronary artery occlusion (%)
Number of implanted stents
Nominal stent diameter (mm)
Total stent length per patient (mm)
Predilation (%)
Cutting balloon (%)
Rotational atherectomy (%)
Directional atherectomy (%)
Postdilatation (%)
Bigger balloon inflated (mm)
Maximal pressure (atm)
Bifurcation stenting (%)
Culotte
T-technique
Crush
Kissing technique
Intravascular ultrasonography (%)
IIb/IIIa inhibitors (%)
Intra-aortic balloon pump (%)
Left ventricle assist device (%)
Temporary pacing during procedure (%)*Location of disease was not mutually exclusive among LM segme
LM  left main coronary artery; other abbreviations as in Tab0.05. All statistical tests were two-tailed. Statistical anal-
sis was performed with Statistica 6.1 software (Statsoft,
ulsa, Oklahoma).
ESULTS
aseline and procedural characteristics. Baseline and pro-
edural characteristics are shown in Tables 1 and 2. The two
roups were well matched for all baseline characteristics. In
oth cohorts, half of the patients presented with a left
entricular ejection fraction of 45% or less or with acute
oronary syndrome as indication to treatment, and 9% of
he patients presented with severe hemodynamic compro-
ise at entry. The distal LM was overall involved in
wo-thirds of cases. In the SES group, nominal stent
iameter was smaller—reflecting the unavailability of stent
igger than 3.0 mm during the study period—and cumula-
ive stent length tended to be shorter than in the PES
roup. Bifurcation stenting was equally employed in both
roups with a clear preference for T-stenting and for culotte
echnique in the SES and PES groups, respectively.
Thirty-one patients (56%) in the SES and 25 (45%) in
he PES group received intervention in one or more non-LM
esion(s) during index procedure (p  0.18). Complete
ics of the Study Population
Group
55)
PES Group
(n  55) p Value
27 22 0.51
29 24 0.54
64 76 0.28
5 5 0.99
18 18 0.99
20 24 0.82
57 53 0.87
69 64 0.88
24 20 0.82
 0.53 1.50  0.6 0.49
 0.25 3.29  0.28 0.001
 11 27  13 0.07
71 60 0.15
7 7 0.99
2 4 0.99
0 0 0.99
82 72 0.15
 0.48 3.70  0.5 0.48
 5 19  3 0.55
29 33 0.84
0 20 0.009
20 5 0.05
7 4 0.67
2 4 0.99
33 27 0.53
33 27 0.68
20 18 0.99
5 0 0.24
7 9 0.99erist
SES
(n 
1.43
3.00
23
3.75
18nts.
le 1.
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Drug-Eluting Stent for LM Treatment February 7, 2006:507–14evascularization was achieved in 27 (49%) patients in the
ES and 36 (65%) in the PES group (p  0.17).
Overall procedural success was 98%. In one patient
eceiving SES, presenting with acute MI and shock, a final
IMI flow grade 1 was obtained. An abrupt irreversible
cclusion of the circumflex occurred in one PES patient
fter deployment of a stent in the left main and proximal left
nterior descending coronary artery (LAD).
hirty-day outcomes. There were no significant differ-
nces between the SES and PES groups in the incidence of
ajor adverse cardiac events (MACE) (death, target vessel
evascularization, or myocardial infarction [MI]) during the
rst 30 days (Table 3). Eight deaths occurred in 10 patients
resenting with ST-segment elevation acute myocardial
nfarction and cardiogenic shock at entry. One elective
atient, undergoing LM treatment under left ventricular
ssist device due to end-stage heart disease, died 2 days after
or cardiogenic shock, while the second elective patients
ied for non-cardiovascular reasons after 19 days. No
ocumented thrombotic stent occlusion occurred in the first
0 days or thereafter.
ong-term clinical outcome. After a median follow-up of
able 3. 30-Day and Long-Term Outcomes
Variables
SES
Group
PES
Group
p
Value*
0-day outcome
Whole population (n  55) (n  55)
Death, n (%) 7 (13) 3 (5) 0.32
Nonfatal MI, n (%) 2 (4) 2 (4) 0.99
Death or nonfatal MI, n (%) 9 (16) 5 (9) 0.40
TVR, n (%) 1 (2) 0 (0) 0.99
Any event, n (%) 10 (18) 5 (9) 0.27
Stent thrombosis, n (%)† 0 (0) 0 (0)
Elective population (n  43) (n  43)
Death, n (%) 2 (5) 0 (0) 0.49
Nonfatal MI, n (%) 2 (5) 2 (5) 0.99
Death or nonfatal MI, n (%) 4 (9) 2 (5) 0.68
TVR, n (%) 1 (2) 0 (0) 0.99
Any event, n (%) 5 (12) 2 (5) 0.44
Stent thrombosis, n (%)† 0 (0) 0 (0) 0.99
ong-term outcome
Whole population (n  55) (n  55)
Death, n (%) 6 (11) 7 (13) 0.70
Nonfatal MI, n (%) 2 (4) 4 (7) 0.25
Death or nonfatal MI, n (%) 9 (16) 10 (18) 0.90
TVR, n (%) 5 (9) 6 (11) 0.67
Any event, n (%) 14 (25) 16 (29) 0.74
Stent thrombosis, n (%)† 0 (0) 0 (0) 0.99
Elective population (n  43) (n  43)
Death, n (%) 2 (5) 2 (5) 0.98
Nonfatal MI, n (%) 2 (5) 4 (9) 0.22
Death or nonfatal MI, n (%) 4 (9) 6 (14) 0.51
TVR, n (%) 5 (12) 5 (12) 0.82
Any event, n (%) 9 (21) 11 (25) 0.55
Stent thrombosis, n (%)† 0 (0) 0 (0) 0.99
By Fischer exact test for 30-day outcome and by log rank test for long-term outcome.
Angiographically documented.
MI  myocardial infarction; TVR  target vessel revascularization; other
bbreviations as in Table 1.60 days (range 428 to 885 days), the cumulative incidence rigure 1. Adverse events in patients treated with sirolimus-eluting stent
SES group) and in patients treated exclusively with paclitaxel-eluting stent
mplantation (PES group). (A) Cumulative risk of major adverse eventsevascularization (TVR). CI  confidence interval.
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February 7, 2006:507–14 Drug-Eluting Stent for LM Treatmentf MACE did not significantly differ in the SES compared
o the PES patients (25% vs. 29%, respectively; hazard ratio
HR] 0.88 [95% confidence interval (CI): 0.43 to 1.82]; p
.74) (Fig. 1A). The composite death/MI was 16% in the
ES and 18% in the PES group (HR 0.95 [95% CI: 0.38 to
.33]; p  0.90) (Fig. 1B), and cumulative incidence of
VR was 9% in the SES and 11% in the PES group (HR
.77 [95% CI: 0.23 to 2.56]; p  0.66) (Fig. 1C).
In the elective patient population (43 patients in each
roup), the cumulative incidence of MACE was similar in
he SES (21%) and PES groups (25%; HR 0.77 [95% CI
.32 to 1.8]; p 0.55). The composite of death/MI was 9%
n the SES and 14% in the PES group (HR 0.66 [95% CI
.19 to 2.3]; p  0.52), and the need for TVR was 12% in
oth groups (HR 0.87 [95% CI 0.24 to 3]; p  0.8).
The cumulative incidence of MACE was similar in
atients receiving single-vessel stenting (24% in the SES
nd 27% in the PES group) and those treated with bifur-
ation stenting (31%, HR 1.38 [95% CI 0.47 to 4]; p 
.55; and 33%, HR 1.22 [95% CI 0.45 to 3.3]; p  0.69;
espectively.
After adjustment for nominal stent diameter and total
tent length at multivariable Cox regression analysis, SES
mplantation as opposed to PES failed to emerge as an
ndependent predictor of MACE (HR 0.79 [95% CI 0.5 to
.5]; p  0.66). The same remained true after forcing the
arsonnet score into the model.
ngiographic outcome. Thirty-five patients in the SES
73% of eligible patients) and 38 patients in the PES group
77% of those eligible) underwent angiographic follow-up.
ata regarding the quantitative coronary angiography for
ain and side branches are presented in Tables 4 and 5,
espectively.
AIN BRANCH. In the SES and PES groups, the main
reated branch circumflex was LM-LAD in 22 (63%) and
1 (55%) patients, respectively followed by LM-circumflex
n 6 (17%) and 8 (21%), LM alone in 5 (14%) and 6 (16%),
nd LM-intermediate branch in 2 (6%) and 3 (8%), respec-
ively. In unprotected patients in the SES and PES groups,
M-LAD was the main treated branch in 77% and in 63%,
espectively, followed by LM alone in 15% and 17%,
M-circumflex in 8% and 14%, and LM-intermediate
ranch in 0% and 6%, respectively.
Baseline and follow-up angiographic variables did not
iffer in the two study groups. No difference was noted in
erms of BR in the two groups as the result of a similar
n-stent and in-lesion LL (Table 4).
IDE BRANCH. All baseline angiographic variables were well
atched between SES and PES groups in the side branches
eceiving stent. At follow-up, both LL and BR were similar
n the two study groups. For those side branches that did not
ndergo stenting as part of LM treatment, despite a bigger
eference vessel diameter in the SES than in the PES group,
he pattern of LL was around zero in both groups (Table 5). iOMBINED ANALYSIS. When both main and side branches
ere evaluated on a patient basis, in-lesion BR occurred in
(20%) and 12 (32%) patients in the SES and PES groups,
espectively (p  0.44). All cases of nonocclusive restenosis
ere focal (length 10 mm).
VUS analysis. Overall, 46 patients (18 in the SES and 28
n the PES group) underwent IVUS investigation at follow-
p. Their baseline and procedural characteristics did not
iffer from those receiving angiographic examination with-
ut IVUS (data not shown). In 11 patients in the SES and 16
n the PES group, LM-LAD was evaluated; the study vessel
as LM-CX in 4 SES and 7 PES and LM alone in 3 SES and
PES patients. In two patients per group, stent malapposition
as noted. As shown in Table 6 the degree of neointimal
yperplasia did not differ between the two study groups.
ISCUSSION
ince their introduction to the market, DES use has steadily
able 4. Quantitative Coronary Angiography Analysis of the
ain Branch
Variables
SES
Group
(n  35)
PES
Group
(n  38)
p
Value
efore procedure
RVD (mm) 3.20  0.57 3.2  0.73 0.82
MLD (mm) 1.26  0.74 1.38  0.49 0.62
Diameter stenosis (%) 60  24 59  16 0.85
Lesion length (mm) 9.5  3.34 10  4.44 0.56
fter procedure
In-stent
RVD (mm) 3.10  0.5 3.2  0.6 0.43
MLD (mm) 2.76  0.5 2.81  0.5 0.32
Acute luminal gain (mm)* 1.50  0.78 1.43  0.75 0.66
Diameter stenosis (%) 10.7  10 10.8  9 0.97
In-lesion
RVD (mm) 2.86  0.6 2.77  0.66 0.54
MLD (mm) 2.47  0.54 2.46  0.58 0.61
Acute luminal gain (mm)* 1.21  0.84 1.10  0.83 0.54
Diameter stenosis (%) 13  10 11  9 0.45
ollow-up
In-stent
RVD (mm) 3.19  0.6 3.01  0.6 0.31
MLD (mm) 2.44  0.85 2.35  0.6 0.60
Diameter stenosis (%) 21.3  25 22.8  19 0.76
Late loss (mm)† 0.32  74 0.46  0.57 0.36
Binary restenosis, n (%)‡ 3 (9) 5 (13) 0.71
Reocclusion, n (%)§ 2 (6) 0 (0) 0.24
In-lesion
RVD (mm) 3.00  0.66 2.89  0.66 0.41
MLD (mm) 2.24  0.83 2.2  0.63 0.77
Diameter stenosis (%) 22  24 22  19 0.97
Late loss (mm)† 0.22  0.73 0.25  0.46 0.86
Binary restenosis, n (%)‡ 3 (9) 4 (11) 0.99
Reocclusion, n (%) 2 (6) 0 (0) 1
Difference between MLD after procedure and MLD before procedure. †Difference
etween MLD at follow-up and MLD after procedure. ‡All non-occlusive restenosis
ere focal (length 10mm). §All two restenotic reocclusions occurred in protected
M lesions.
MLD  minimal lumen diameter; PES  paclitaxel-eluting stent; RVD 
eference vessel diameter; SES  sirolimus-eluting stent.ncreased. Depending on the health care system, they are
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Drug-Eluting Stent for LM Treatment February 7, 2006:507–14ow partially or almost completely replacing bare-metal
tents (BMS) during coronary intervention.
Recently, some concerns for the consequences of using
hese devices liberally have been raised, which emphasizes
he need to scrutinize those patient/lesion subsets that were
xcluded from landmark randomized trials, particularly beyond
onventional eight to nine months’ follow-up (14–17). Yet
n both controlled and observational studies, a potential
ifferential efficacy and safety profile between SES and PES
as been observed, especially in patient populations consid-
red to be at higher risk for adverse events. Thus, current
vailable evidence reinforces the idea that it would be improper
o attribute a class effect to DES and that a high-risk patient
opulation should be better evaluated to further compare
he safety/efficacy profile of these two stents.
The percutaneous management of LM lesions is a chal-
enging intervention, where bifurcated vessels, extensive
all calcification, and poor hemodynamic tolerance often
able 5. Quantitative Coronary Angiography Analysis in the Sid
Stented Branches
Variables SES Group PES Group
efore procedure n  12 n  15
RVD (mm) 2.63  0.67 2.70  0.61
MLD (mm) 1.16  0.52 1.27  0.77
Diameter stenosis (%) 56  21 54  24
Lesion length (mm) 10  4 11  8
fter procedure
RVD (mm) 2.73  0.79 2.85.0  0.57
MLD in-stent (mm) 1.95  0.43 2.32  0.45
MLD in-lesion (mm) 1.9  0.38 2  0.55
ALG in-stent (mm) 0.79  0.57 1  0.6
ALG in-lesion (mm) 0.72  0.55 0.75  0.76
Diameter stenosis (%) 25  18 18  11
ollow-up
RVD (mm) 2.70  0.54 2.56  0.60
MLD in-stent (mm) 1.6  0.45 1.8  0.49
MLD in-lesion (mm) 1.54  0.58 1.62  0.65
Diameter stenosis (%) 39  23 29  25
LL in-stent (mm) 0.36  0.59 0.52  0.42
LL in-lesion (mm) 0.33  0.42 0.39  0.62
BR in-stent, n (%)* 3 (25) 3 (20)
BR in-lesion, n (%)* 3 (25) 2 (13)
Reocclusion, n (%) 2 (6) 0 (0)
All non-occlusive restenosis were focal (length 10 mm).
ALG  acute luminal gain; BR  binary restenosis; LL  late loss; other abbre
able 6. Quantitative Intravascular Ultrasound (IVUS) Results
IVUS Variables
SES Group
n  18
PES Group
n  28
p
Value
VUS volumes (mm3)
Luminal 237  183 250  167 0.80
Vessel 473  371 528  351 0.63
Stent 256  194 267  174 0.81
Intimal hyperplasia 19.3  26 28  60 0.44
Intimal hyperplasia/10 mm* 6.3  9 9.6  13 0.74
ercentage intimal hyperplasia (%) 7.5  8 10  14 0.68
Calculated as intimal hyperplasia volume divided by the length of the region of
nterest expressed in mm (24  19 in the SES and 29  19 in the PES group; p 
.49), multiplied by 10.
PES  paclitaxel-eluting stent; SES  sirolimus-eluting stent.oexist during treatment as natural extensions of the ana-
omic characteristics of the lesions (18,19). Moreover,
ercutaneous LM intervention, being usually reserved to
oor surgical candidates, is often undertaken in patients
ith low ejection fraction or renal dysfunction, which are
nown predictors of adverse events even in patients receiv-
ng DES (16).
The main results of our analysis show that, as predicted
y the risk status of the patients, the overall event rate was
igher than that previously reported for non-LM lesions.
owever, the safety/efficacy profile of the two DES evalu-
ted was apparently maintained at long-term follow-up,
ith PES performing closely to SES in terms of both
linical and angiographic outcome.
This statement is based on the following findings:
. The great majority of events occurred in both groups
within one year, considering either the whole (86% in
the SES and 81% in the PES) or the elective population
(78% in the SES and 73% in the PES group). No early
or late angiographically confirmed stent thrombosis has
been observed, with only one sudden death occurring in
an 86-year-old woman affected by a hematological
malignancy seven months after the index procedure.
. The short- and long-term clinical event rate in the two
study groups was not different, and at multivariable
analysis the stent implanted failed to emerge as an
independent predictor of adverse events.
. Angiographic and IVUS investigation demonstrated
that late loss and neointimal hyperplasia volume were
nches
Nonstented Branches
p Value SES Group PES Group p Value
n  21 n  23
0.69 2.44  0.72 2.00  0.55 0.02
0.69 1.68  72 1.47  0.67 0.31
0.61 27  28 26  25 0.96
0.76 5.7  3 4.9  2.1 0.30
0.65 2.26  0.7 2.00  0.6 0.12
0.041 — —
0.46 1.7  0.58 1.48  0.69 0.27
0.62 — —
0.89 0.01  0.66 0.009  0.5 0.97
0.17 23  25 20  23 0.66
0.40 2.30  0.69 2.00  0.55 0.20
0.35 — —
0.73 1.83  0.63 1.40  0.77 0.059
0.24 21  14 33  32 0.13
0.41 — —
0.78 0.13  0.44 0.07  0.62 0.23
0.99 — —
0.63 1 (5) 6 (26) 0.10
0.24 0 (0) 2 (9) 0.49
s as in Table 4.e Brasimilar in the two groups of patients. The angiographic
A
d
b
S
w
s
R
S
S
t
e
i
t
i
m
t
d
w
e
t
t
l
r
p
m
h
c
t
(
d
o
m
n
r
s
r
b
i
b
p
b
o
a
f
L
0
u
l
p
n
g
a
t
P
i
u
f
D
w
t
t
p
p
c
v
s
S
e
a
d
r
i
t
t
a
t
s
C
T
l
s
t
c
t
S
l
t
t
o
i
t
D
b
S
r
T
u
n
p
513JACC Vol. 47, No. 3, 2006 Valgimigli et al.
February 7, 2006:507–14 Drug-Eluting Stent for LM Treatmentoutcome of the nonstented side branches was also
remarkably similar between the two groups.
mong these observations, the last one was unexpected and
eserves special attention.
In all major randomized controlled trials evaluating the
enefit of SES versus BMS, the average in-stent LL for
ES was reported to be constantly equal to or below 0.20,
hereas the same figure for PES, based on PES versus BMS
tudies, was around two times higher. The Prospective,
andomized, Multi-Center, Comparison of the Cypher
irolimus-Eluting and the Taxus Paclitaxel-Eluting Stent
ystems (REALITY) study showed a difference between
hese two DES in terms of angiographic end points that was
ven bigger, with a mean in-stent LL of 0.9 in SES and 0.31
n the PES group (5). Conversely, in the current investiga-
ion we failed to show any difference between the two stents
n terms of in-stent or in-segment LL or BR, either in the
ain branch or in the stented side branches. Interestingly,
his was confirmed by the IVUS analysis. Although the
ifference was more striking for SES, the LL in both groups
ere actually much higher than the figures expected. The
xplanation for this discrepancy can only be speculative for
he moment and it may suggest that angiographic response
o DES is lesion/patient-specific. Data so far available in the
iterature are inconclusive in this regard. Park et al. (2)
ecently reported an average late loss of 0.05 mm in 102
atients receiving SES for the treatment of unprotected left
ain disease, whereas the same figure in 85 LM patients at
igher risk status, treated with either PES or SES, was
umulatively reported to be 0.58 mm (3). Unfortunately, in
hat study no distinction between SES and PES was made
3).
The lack of availability of SES sizes bigger than 3.0 mm
uring the study period, which imposed an aggressive
verdilation strategy to match LM reference diameter,
ight have theoretically played a role. However, this tech-
ical issue was at least partially encountered in the series
eported by Park et al. (2) as well.
Alternatively, this difference between studies could pos-
ibly reflect a selection bias, with patients at higher clinical
isk based on previous cardiovascular history and comor-
idities being more prone to develop a more aggressive
ntimal proliferation after DES. To investigate this possi-
ility in an exploratory fashion (this analysis was not
respecified for the current study), we pooled the LL for
oth main branch and all stented side branches as the
utcome variable in a linear regression model. At univariate
nalysis including all variables reported in Tables 1 and 2 we
ound protected status to be the strongest predictor for high
L ( 0.47 [95% CI 0.24 to 0.7]; p 0.001; adjusted R2
.39). Accordingly, we observed that in patients receiving
nprotected LM intervention (n 59) LL was cumulatively
ower (0.31  0.41 vs. 0.63  72; p  0.037) than in
atients receiving protected treatment (n  14), and, of tote, all occlusive binary restenosis occurred in the protected
roup of patients.
Interestingly, none of the variables reported in Tables 1
nd 2 differed significantly between patients receiving pro-
ected versus unprotected LM intervention, with the overall
arsonnet score being 16  7.5 in protected versus 18  10
n unprotected patients (p  0.4).
The observed difference in LL between protected versus
nprotected LM intervention might possibly outline a role
or shear stress as potential modulator of vessel response to
ES, as recently suggested by our group (20). This analysis
as exploratory in nature and clearly beyond the scope of
he current investigation. However, it underscores the need
o consider DES performance in the context of the patient
opulation in which the device was actually tested.
Taken together, our observations suggest that DES may
erform more effectively in good than in poor surgical
andidates, which reinforces the interest in assessing the
alue of this treatment as compared with conventional
urgical approach in a properly designed randomized trial.
tudy limitations. The present study is a single-center
xperience from a tertiary referral center and lacks the clear
dvantages of a multicenter randomized study. In particular,
espite the fact that the study was conducted over a
elatively short period, we cannot exclude the possibility that
mprovements in technique or differences in drug prescrip-
ion could have partially confounded our main results.
Accordingly, the results of our study are encouraging, but
hey cannot be conclusive. Studies with bigger sample sizes
nd more prolonged clinical follow-ups are clearly required
o rule out the occurrence of less common device-related
ide effects.
linical implications of the combined RESEARCH and
-SEARCH analysis. In the overall results of the unse-
ected RESEARCH versus T-SEARCH comparison, a
hift toward more complex lesions has been noted from SES
o PES cohort (8). This difference was not confirmed in our
urrent analysis, which focused on LM lesions cumulatively
reated over a longer period of time: more patients in the
ES group received concomitant intervention in non-LM
esions and fewer reached complete revascularization than in
he PES cohort. However, the stent length was greater in
he PES group. When this finding is combined with the
bserved shift from T-stenting in the SES period to culotte
n the PES period as bifurcation technique, it may suggest
hat operators have become progressively more familiar with
ES over time and that full lesion coverage with DES had
een more frequently performed in the PES than in the
ES group. The impact of these confounders on our final
esult remains incompletely understood.
When taken together, the combined RESEARCH and
-SEARCH analysis may reinforce the concept that in an
ncontrolled setting such as our clinical practice, the coro-
ary device in itself should probably be regarded among the
rincipal but clearly not as the only component of the long-
erm procedural success in the DES era. Rather, the two
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Drug-Eluting Stent for LM Treatment February 7, 2006:507–14rug-eluting stents available on the market should always be
ut in the context of the characteristics of the treated
atients and the operator’s experience to better forecast their
ffect on short- and long-term outcome.
onclusions. After a median follow-up of two years, no
ate serious adverse events, possibly suggesting a time-
ependent change in the therapeutic profile of the investi-
ated devices, were observed.
In a consecutive group of patients undergoing percutane-
us LM intervention, PES may perform closely to SES in
erms of both clinical and angiographic outcome.
A multinational multicenter randomized study is currently
ngoing to estimate the clinical value of PES-supported LM
ntervention with respect to conventional surgical treatment.
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